Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Virginia Brady MD
Virginia A. Brady MD Associate Editor
Geoffrey Connors MD, FACP
Geoffrey R. Connors MD, FACP Associate Editor
Shyoko Honiden MD, MSc
Shyoko Honiden MD, MSc Editor-in-Chief
See All Experts
Published in Respiratory Medicine

Journal Scan / Research · November 29, 2024

Effect of Solriamfetol on Cognitive Function in Patients With Obstructive Sleep Apnea With Excessive Daytime Sleepiness and Cognitive Impairment

Chest

 

 Save  Recommend
 Share

Additional Info

Disclosure statements are available on the authors' profiles:

Emmett Kistler MD

Chest
Results of the SHARP Study: A Randomized, Placebo-Controlled, Double-Blind, Repeated-Measures, Crossover, Phase IV Clinical Trial of the Effect of the Wake-Promoting Agent Solriamfetol on Cognitive Function in Obstructive Sleep Apnea With Excessive Daytime Sleepiness and Cognitive Impairment
Chest 2024 Nov 09;[EPub Ahead of Print], HPA Van Dongen, EB Leary, C Drake, R Bogan, J Jaeger, R Rosenberg, C Streicher, H Tabuteau

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading

Most Read This Week

Recently Updated